Regenstrief Institute

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Regenstrief Institute

Regenstrief Institute is a dynamic, people-centered research organization driven by a mission to create pathways for better health. We envision a world where every patient has access to the highest quality, most efficient healthcare available, at an affordable cost. We pursue this vision through research and development guided by our core values: DISCOVERY, Making every effort to facilitate and support scientific inquiry; IMPACT, Rapidly disseminating research discoveries into practice and patient care; CAPABILITY, Creating opportunity for breakthrough research by evolving an environment rich in resources; COMMUNITY, Sharing knowledge and forming partnerships.
The schools main facilities are located on the campus of Indiana University – Purdue University Indianapolis (IUPUI) in Indianapolis, Indiana. Additionally, the school maintains eight regional centers on college campuses throughout the state at Bloomington, Muncie, Fort Wayne, South Bend, Terre Haute, Evansville, West Lafayette, and Gary.
First- and second-year students attend classes at either the main campus at IUPUI in Indianapolis (approximately half of the class) or at one of the eight regional centers. In the past, third- and fourth-year students spent the last two years of medical school at the IUPUI campus. In recent years clinical clerkships have been added to regional campuses, where students can choose to spend third- and fourth-year.
The VanNuys Medical Sciences Building at the IUPUI campus houses the DNA Tower sculpture by Dale Chihuly.
Students at IUSM hail from both home state and out-of-state, at a ratio of 1,516 to 543. There were 6,146 applicants for the 2015–16 cycle. The average GPA of that entering class of 2015 was 3.74, and the average MCAT score was a 30/0.
The School is notable for its Tour the Life Student Blogs, in which medical students from all years write about their academic, clinical, and personal experiences at IUSM.
The School offers several combined degree programs: the MD-PhD, MD-MBA, MD-MPH, and MD-MA. The MD-MBA is in conjunction with the Kelley School of Business. The MD-PhD program, which offers full-tuition and stipend to acceptees for all years of training, is one of 40 medical schools to be designated an MSTP by the NIH. Typically about five students a year are accepted into the MD-PhD program at IUSM. MD-PhD students can choose to conduct research with faculty at either the medical school or at Purdue University.
The school holds a first in developing the use of echocardiography, a heart imaging technique using ultrasound. In the 1960s, Mori Aprison discovered the inhibitory neurotransmitter glycine. Another neuroscientist and faculty member at IUSM, Dr. Paul Stark, led the clinical team at Eli Lilly and Company in the development of Prozac, the most widely prescribed antidepressant. In 1984, IUSM established the first DNA "bank" in the world; blood samples from clients were used to extract DNA which could indicate the genetic risk for certain illnesses and conditions. The school researchers also discovered the use of cord blood as an alternative source of hematopoietic stem cells and pioneered their use in the clinic. In the early 1990s, the School was one of the first institutions to study the use of computer systems in reducing the costs of healthcare management. The school is known for establishing a curative therapy for testicular cancer. Patients from around the world, including Tour de France winner Lance Armstrong, have traveled to the Melvin and Bren Simon Cancer Center for this therapy and comprehensive care. The school has been a pioneer in establishing a cure for Fanconi Anemia (a precancerous condition in children), specific radiation therapy techniques, techniques in a type of nerve-sparing surgery for urological cancers, the development of drugs to stimulate blood cell production, and novel drug therapies for breast cancer. Researchers at the medical school also discovered the cancer-fighting agent in Tamoxifen. In 2011, the school announced plans for an institute specializing in personalized medicine, which would pursue an individualized and genomics-based approach to treating cancer, pediatrics, and obstetrics. IU School of Medicine is a leader in the research, diagnosis, treatment and rehabilitation of traumatic brain injury and mild traumatic brain injury.

The following is the list of scholars from Regenstrief Institute who contributed and/or serves as editors for one or more OMICS International journals and conferences